• Test Code:
  • Department:
    Molecular Genetics
  • Test Synonyms:
    ACTB • ACTG1 • AHI1 • ARFGEF2 • ARL13B • ARX • ASPM • ATR • ATRX • C5ORF42 • CASK • CC2D2A • CDK5RAP2 • CDKL5 • CDON • CENPJ • CEP152 • CEP290 • CEP41 • COL4A1 • CUL4B • DCX • DHCR7 • DISP1 • DLL1 • EMX2 • EOMES • EXOSC3 • EZH2 • FGF8 • FKRP • FKTN • FLNA • FOXG1 • FOXH1 • GAS1 • GLI2 • GLI3 • GPR56 • HESX1 • IER3IP1 • KIAA1279 • KIF7 • L1CAM • LAMC3 • LARGE • MCPH1 • MECP2 • MED12 • MKS1 • MRPS16 • MYCN • NFIX • NIPBL • NODAL • NPHP1 • NSD1 • OFD1 • OPHN1 • OTX2 • PAFAH1B1 • PCNT • PHF6 • PIK3CA • POMGNT1 • POMT1 • POMT2 • PQBP1 • PTCH1 • PTEN • RAB18 • RAB3GAP1 • RAB3GAP2 • RARS2 • RBBP8 • RELN • RPGRIP1L • SHH • SIX3 • SLC25A19 • SLC9A6 • SOX2 • SRPX2 • STIL • TCF4 • TCTN1 • TCTN2 • TGIF1 • TMEM138 • TMEM216 • TMEM237 • TMEM67 • TSEN2 • TSEN34 • TSEN54 • TTC21B • TUBA1A • TUBA8 • TUBB2B • TUBB3 • UBE3A • UPF3B • VLDLR • VRK1 • WDR62 • ZEB2 • ZIC2
  • CPT Code(s):
    Contact KDL for billing information
Background:

Disorders causing brain malformations are phenotypically heterogeneous; mutations in certain genes have been associated inherited conditions causing brain developmental issues. These conditions could present with dysmorphologic features including holoprosencephaly, microcephaly and macrocephaly. Other clinical phenotypes include dysmorphologies observed in MRIs, seizures, developmental delays and intellectual disability. These conditions could include lissencephalies, cerebellar hypoplasia, Joubert syndrome and Joubert-like disorders. Conditions causing brain malformations can be inherited in an autosomal dominant, recessive and X-linked pattern.

Reasons for Referral:

  • Suspected genetic etiology of a brain malformation
  • Carrier testing
  • Positive family history

For detailed information and ordering instructions, please refer to Full Gene Analysis (1240). Genes may be added or removed from the list below if clinically indicated.

Coding region coverage for the Comprehensive Brain Malformations panel genes:
ACTB, ACTG1, AHI1, ARFGEF2, ARL13B, ARX, ASPM, ATR, ATRX, C5ORF42, CASK, CC2D2A, CDK5RAP2, CDKL5, CDON, CENPJ, CEP152, CEP290, CEP41, COL4A1, CUL4B, DCX, DHCR7, DISP1, DLL1, EMX2, EOMES, EXOSC3, EZH2, FGF8, FKRP,FKTN, FLNA, FOXG1, FOXH1, GAS1, GLI2, GLI3, GPR56, HESX1, IER3IP1, KIAA1279, KIF7, L1CAM, LAMC3, LARGE, MCPH1, MECP2, MED12, MKS1, MRPS16, MYCN, NFIX, NIPBL, NODAL, NPHP1, NSD1, OFD1, OPHN1, OTX2, PAFAH1B1, PCNT, PHF6, PIK3CA, POMGNT1, POMT1, POMT2, PQBP1, PTCH1, PTEN, RAB18, RAB3GAP1, RAB3GAP2, RARS2, RBBP8, RELN, RPGRIP1L, SHH, SIX3, SLC25A19, SLC9A6, SOX2, SRPX2, STIL, TCF4, TCTN1, TCTN2, TGIF1, TMEM138, TMEM216, TMEM237, TMEM67, TSEN2, TSEN34, TSEN54, TTC21B, TUBA1A, TUBA8, TUBB2B, TUBB3, UBE3A, UPF3B, VLDLR, VRK1, WDR62, ZEB2, ZIC2

Methodology:

Specimen Requirements:

Test Performed (Days):

Turn Around Time:

Shipment Sensitivity Requirements:

References:

Additional Info:

Contact Us
Innovations in Testing
View All Tests

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More